Free Trial
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel Free TEVA Stock Alerts

Teva Pharmaceutical Industries (TEVA) Competitors

Teva Pharmaceutical Industries logo
$39.05 -0.61 (-1.54%)
Closing price 03:59 PM Eastern
Extended Trading
$38.82 -0.23 (-0.60%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TEVA vs. ABBV, NVO, PFE, BMY, and SNY

Should you buy Teva Pharmaceutical Industries stock or one of its competitors? Teva Pharmaceutical Industries's main competitors and comparable companies include AbbVie (ABBV), Novo Nordisk A/S (NVO), Pfizer (PFE), Bristol Myers Squibb (BMY), and Sanofi (SNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Teva Pharmaceutical Industries compare to AbbVie?

Teva Pharmaceutical Industries (NYSE:TEVA) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AbbVie has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.68$1.41B$0.6066.04
AbbVie$61.16B7.68$4.23B$3.5475.12

Teva Pharmaceutical Industries presently has a consensus price target of $44.67, indicating a potential upside of 12.73%. AbbVie has a consensus price target of $272.39, indicating a potential upside of 2.43%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities analysts clearly believe Teva Pharmaceutical Industries is more favorable than AbbVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.92
AbbVie
0 Sell rating(s)
6 Hold rating(s)
22 Buy rating(s)
2 Strong Buy rating(s)
2.87

AbbVie has a net margin of 9.80% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
AbbVie 9.80%-422.07%14.34%

Teva Pharmaceutical Industries has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

In the previous week, AbbVie had 42 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 66 mentions for AbbVie and 24 mentions for Teva Pharmaceutical Industries. AbbVie's average media sentiment score of 0.74 beat Teva Pharmaceutical Industries' score of 0.55 indicating that AbbVie is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
6 Very Positive mention(s)
4 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
28 Very Positive mention(s)
10 Positive mention(s)
22 Neutral mention(s)
4 Negative mention(s)
2 Very Negative mention(s)
Positive

Summary

AbbVie beats Teva Pharmaceutical Industries on 12 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Novo Nordisk A/S?

Teva Pharmaceutical Industries (NYSE:TEVA) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Novo Nordisk A/S has a net margin of 35.36% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Novo Nordisk A/S's return on equity of 58.61% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Novo Nordisk A/S 35.36%58.61%20.91%

Teva Pharmaceutical Industries has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Novo Nordisk A/S has higher revenue and earnings than Teva Pharmaceutical Industries. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.68$1.41B$0.6066.04
Novo Nordisk A/S$46.80B3.58$15.51B$4.099.18

Teva Pharmaceutical Industries currently has a consensus target price of $44.67, indicating a potential upside of 12.73%. Novo Nordisk A/S has a consensus target price of $102.85, indicating a potential upside of 173.94%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.92
Novo Nordisk A/S
4 Sell rating(s)
17 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.07

In the previous week, Novo Nordisk A/S had 23 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 47 mentions for Novo Nordisk A/S and 24 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.55 beat Novo Nordisk A/S's score of 0.31 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
6 Very Positive mention(s)
4 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
20 Very Positive mention(s)
9 Positive mention(s)
8 Neutral mention(s)
8 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Novo Nordisk A/S beats Teva Pharmaceutical Industries on 9 of the 16 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Pfizer?

Teva Pharmaceutical Industries (NYSE:TEVA) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries currently has a consensus target price of $44.67, indicating a potential upside of 12.73%. Pfizer has a consensus target price of $28.39, indicating a potential upside of 3.55%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Pfizer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.92
Pfizer
2 Sell rating(s)
14 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.19

Pfizer has higher revenue and earnings than Teva Pharmaceutical Industries. Pfizer is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.68$1.41B$0.6066.04
Pfizer$62.58B2.50$7.77B$0.7636.07

In the previous week, Pfizer had 37 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 61 mentions for Pfizer and 24 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.55 beat Pfizer's score of 0.35 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
6 Very Positive mention(s)
4 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pfizer
24 Very Positive mention(s)
10 Positive mention(s)
20 Neutral mention(s)
5 Negative mention(s)
2 Very Negative mention(s)
Neutral

Pfizer has a net margin of 6.80% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Pfizer 6.80%19.63%8.46%

Teva Pharmaceutical Industries has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Summary

Pfizer beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Bristol Myers Squibb?

Teva Pharmaceutical Industries (NYSE:TEVA) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Teva Pharmaceutical Industries currently has a consensus price target of $44.67, suggesting a potential upside of 12.73%. Bristol Myers Squibb has a consensus price target of $67.00, suggesting a potential upside of 14.08%. Given Bristol Myers Squibb's higher probable upside, analysts plainly believe Bristol Myers Squibb is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.92
Bristol Myers Squibb
1 Sell rating(s)
11 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.56

In the previous week, Bristol Myers Squibb had 8 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 32 mentions for Bristol Myers Squibb and 24 mentions for Teva Pharmaceutical Industries. Bristol Myers Squibb's average media sentiment score of 0.61 beat Teva Pharmaceutical Industries' score of 0.55 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
6 Very Positive mention(s)
4 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bristol Myers Squibb
10 Very Positive mention(s)
8 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Bristol Myers Squibb has higher revenue and earnings than Teva Pharmaceutical Industries. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.68$1.41B$0.6066.04
Bristol Myers Squibb$48.19B2.49$7.05B$4.5412.94

Bristol Myers Squibb has a net margin of 18.87% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Bristol Myers Squibb's return on equity of 66.90% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Bristol Myers Squibb 18.87%66.90%14.74%

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bristol Myers Squibb beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Sanofi?

Sanofi (NASDAQ:SNY) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Sanofi has higher revenue and earnings than Teva Pharmaceutical Industries. Sanofi is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B1.94$8.84B$1.9120.69
Teva Pharmaceutical Industries$17.26B2.68$1.41B$0.6066.04

In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Sanofi. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 14 mentions for Sanofi. Teva Pharmaceutical Industries' average media sentiment score of 0.55 beat Sanofi's score of 0.46 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
3 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Teva Pharmaceutical Industries
6 Very Positive mention(s)
4 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

14.0% of Sanofi shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sanofi has a net margin of 8.66% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.66% 14.19% 7.95%
Teva Pharmaceutical Industries 4.08%32.64%6.34%

Sanofi presently has a consensus target price of $49.50, indicating a potential upside of 25.28%. Teva Pharmaceutical Industries has a consensus target price of $44.67, indicating a potential upside of 12.73%. Given Sanofi's higher possible upside, equities research analysts clearly believe Sanofi is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
1 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.38
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.92

Sanofi has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Sanofi on 9 of the 17 factors compared between the two stocks.

Get Teva Pharmaceutical Industries News Delivered to You Automatically

Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TEVA vs. The Competition

Export
MetricTeva Pharmaceutical IndustriesPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$46.22B$12.19B$7.19B$22.91B
Dividend YieldN/A2.65%2.53%3.72%
P/E Ratio65.08799.76273.3628.10
Price / Sales2.64756.56585.5424.25
Price / Cash10.6387.1279.4136.95
Price / Book5.6810.6311.044.72
Net Income$1.41B$2.84B$3.49B$1.07B
7 Day Performance-1.99%-2.19%-2.30%0.89%
1 Month Performance7.39%-6.91%-7.05%-4.97%
1 Year Performance95.34%-4.98%5.64%5.65%

Teva Pharmaceutical Industries Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEVA
Teva Pharmaceutical Industries
3.8649 of 5 stars		$39.05
-1.5%		$44.67
+14.4%		+98.1%$46.22B$17.26B65.0833,950
ABBV
AbbVie
4.1301 of 5 stars		$266.39
+0.8%		$272.66
+2.4%		+13.6%$467.03B$61.16B75.2557,000
NVO
Novo Nordisk A/S
4.4078 of 5 stars		$38.69
-0.3%		$64.94
+67.8%		-37.1%$173.24B$46.80B9.4669,505
PFE
Pfizer
3.0074 of 5 stars		$28.76
+0.3%		$28.39
-1.3%		+0.2%$163.41B$62.58B37.8475,000
BMY
Bristol Myers Squibb
4.7981 of 5 stars		$63.84
+1.6%		$67.06
+5.0%		+29.4%$128.41B$48.19B14.0632,500

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:TEVA) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
Nvidia’s record quarter could send this new type of AI soaring
Nvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...
Brownstone Research | Sponsoredtc pixel
They're not telling you how bad this could get
Valuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...
Parkview Capital Group | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel